Last reviewed · How we verify
Nivolumab starting at day -1
Nivolumab starting at day -1 is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development.
At a glance
| Generic name | Nivolumab starting at day -1 |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer (PHASE2)
- Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV (PHASE1)
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma (PHASE1, PHASE2)
- PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PHASE1, PHASE2)
- A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (PHASE2)
- Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma (PHASE1, PHASE2)
- Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nivolumab starting at day -1 CI brief — competitive landscape report
- Nivolumab starting at day -1 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Nivolumab starting at day -1
What is Nivolumab starting at day -1?
Nivolumab starting at day -1 is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.
Who makes Nivolumab starting at day -1?
Nivolumab starting at day -1 is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).
What development phase is Nivolumab starting at day -1 in?
Nivolumab starting at day -1 is in Phase 1.